Global APOL1 Mediated Kidney Disease 麻豆原创 Research Report 2023

Publication ID:

PB510231895

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body鈥檚 built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.
The global APOL1 Mediated Kidney Disease market is projected to reach US$ 1218.5 million in 2029, increasing from US$ 812 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole APOL1 Mediated Kidney Disease market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global APOL1 Mediated Kidney Disease market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Vertex Pharmaceuticals
Ionis Pharmaceuticals
Travere Therapeutics
ChemoCentryx
ZyVersa Therapeutics
GlaxoSmithKline
Novartis
Teva Pharmaceuticals
Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The APOL1 Mediated Kidney Disease report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global APOL1 Mediated Kidney Disease 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Small Molecule
1.2.3 Gene Modification
1.2.4 Nucleic Acid Therapies
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global APOL1 Mediated Kidney Disease 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Chronic Kidney Disease
1.3.3 End Stage Kidney Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global APOL1 Mediated Kidney Disease 麻豆原创 Perspective (2018-2029)
2.2 APOL1 Mediated Kidney Disease Growth Trends by Region
2.2.1 Global APOL1 Mediated Kidney Disease 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 APOL1 Mediated Kidney Disease Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 APOL1 Mediated Kidney Disease Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 APOL1 Mediated Kidney Disease 麻豆原创 Dynamics
2.3.1 APOL1 Mediated Kidney Disease Industry Trends
2.3.2 APOL1 Mediated Kidney Disease 麻豆原创 Drivers
2.3.3 APOL1 Mediated Kidney Disease 麻豆原创 Challenges
2.3.4 APOL1 Mediated Kidney Disease 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue
3.1.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue (2018-2023)
3.1.2 Global APOL1 Mediated Kidney Disease Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global APOL1 Mediated Kidney Disease 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by APOL1 Mediated Kidney Disease Revenue
3.4 Global APOL1 Mediated Kidney Disease 麻豆原创 Concentration Ratio
3.4.1 Global APOL1 Mediated Kidney Disease 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by APOL1 Mediated Kidney Disease Revenue in 2022
3.5 APOL1 Mediated Kidney Disease Key Players Head office and Area Served
3.6 Key Players APOL1 Mediated Kidney Disease Product Solution and Service
3.7 Date of Enter into APOL1 Mediated Kidney Disease 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 APOL1 Mediated Kidney Disease Breakdown Data by Type
4.1 Global APOL1 Mediated Kidney Disease Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global APOL1 Mediated Kidney Disease Forecasted 麻豆原创 Size by Type (2024-2029)
5 APOL1 Mediated Kidney Disease Breakdown Data by Application
5.1 Global APOL1 Mediated Kidney Disease Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global APOL1 Mediated Kidney Disease Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America APOL1 Mediated Kidney Disease 麻豆原创 Size (2018-2029)
6.2 North America APOL1 Mediated Kidney Disease 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2018-2023)
6.4 North America APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe APOL1 Mediated Kidney Disease 麻豆原创 Size (2018-2029)
7.2 Europe APOL1 Mediated Kidney Disease 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2018-2023)
7.4 Europe APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific APOL1 Mediated Kidney Disease 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific APOL1 Mediated Kidney Disease 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific APOL1 Mediated Kidney Disease 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific APOL1 Mediated Kidney Disease 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America APOL1 Mediated Kidney Disease 麻豆原创 Size (2018-2029)
9.2 Latin America APOL1 Mediated Kidney Disease 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2018-2023)
9.4 Latin America APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa APOL1 Mediated Kidney Disease 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa APOL1 Mediated Kidney Disease 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa APOL1 Mediated Kidney Disease 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Detail
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.1.4 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Detail
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.2.4 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Travere Therapeutics
11.3.1 Travere Therapeutics Company Detail
11.3.2 Travere Therapeutics Business Overview
11.3.3 Travere Therapeutics APOL1 Mediated Kidney Disease Introduction
11.3.4 Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.3.5 Travere Therapeutics Recent Development
11.4 ChemoCentryx
11.4.1 ChemoCentryx Company Detail
11.4.2 ChemoCentryx Business Overview
11.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Introduction
11.4.4 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.4.5 ChemoCentryx Recent Development
11.5 ZyVersa Therapeutics
11.5.1 ZyVersa Therapeutics Company Detail
11.5.2 ZyVersa Therapeutics Business Overview
11.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Introduction
11.5.4 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.5.5 ZyVersa Therapeutics Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Introduction
11.6.4 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.6.5 GlaxoSmithKline Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis APOL1 Mediated Kidney Disease Introduction
11.7.4 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Detail
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.8.4 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
11.8.5 Teva Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Vertex Pharmaceuticals
Ionis Pharmaceuticals
Travere Therapeutics
ChemoCentryx
ZyVersa Therapeutics
GlaxoSmithKline
Novartis
Teva Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.